Ipca Laboratories has launched India's first Etodolac, called Etova. It is a new generation pain manager that is considerably safer than Coxibs which have been linked to cardiovascular side-effects.
Etova is a preferential COX II inhibitor, and is a safe and effective pain relieving agent. It is approved by US FDA.
Pain management is a growing area of activity, with the increased incidence of dental pain, arthritis pain, lower back pain, injuries, and post surgical pain. Conventional pain killers have been found wanting in treating pain due to their high rate of gastric side effects. Coxibs, or non-steroidal anti-inflammatory drugs, were launched to overcome these side effects of conventional pain killers, but Coxibs themselves are in decline worldwide as they are associated with a high degree of cardiovascular side effects.
Ipca has introduced other pain managers like Zerodol and Movon (Aceclofenac), and also HCQS (Hydroxychloroquine). With the launch of Etova, India's first Etodolac, Ipca will be consolidating its position in the pain management category.